ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Estrogen receptor (ER) signaling is crucial for hormone receptor-positive (HR+) breast cancer growth.
• The ER-cyclin D1-CDK4/6-RB pathway regulates the cell cycle, and CDK4/6 inhibitors target this pathway.
• ER+/HER2- breast cancers benefit from combining CDK4/6 inhibitors with endocrine therapies.

Purpose of the Study:

• To elucidate the synergistic mechanism of antiestrogen (fulvestrant) and CDK4/6 inhibitors in ER-mediated cell cycle suppression.
• To investigate the role of ER and retinoblastoma (RB) levels in patient-derived xenograft (PDX) models treated with palbociclib.

Main Methods:

• Single cell analysis of cells from an estrogen-dependent, HR+ PDX model.
• Treatment of the PDX model with palbociclib and assessment of ER and RB expression levels.

Main Results:

• Combination therapy exhibits synergism in suppressing ER-mediated cell cycle progression.
• Palbociclib response is dependent on elevated levels of ER and/or RB.
• Preclinical studies confirm palbociclib response is linked to ER expression in HR+ breast cancer.

Conclusions:

• The combination of fulvestrant and CDK4/6 inhibitors offers a synergistic approach to target ER-mediated cell cycle progression.
• Therapeutic response to CDK4/6 inhibitors like palbociclib in HR+ breast cancer is influenced by ER and RB expression levels.
• Understanding these molecular dependencies can inform treatment strategies for HR+ breast cancer.